Intraday Info: Immune Pharmaceuticals Inc (NASDAQ:IMNP) locked on 19/12/2016 at $0.184. It has average volume $7.22 million whilst it total volume $4.29. The company has EPS -0.73 and according to analysts next quarter EPS and next year estimate EPS will -0.11 and 0.51 respectively. And it total income 97.10 million.
Ownership Summary: Immune Pharmaceuticals Inc has total institutional ownership 2.12% while its total outstanding shares 142 millions that’s value of holdings $1 million.
Active Positions: In the latest year, IMNP 10 holders have raised its positions while it contains total 2,642,761 shares. And the strength of reduced positions holders and held positions holders are 3 and 3 respectively.
New and Sold Out Positions: In IMNP force of new positions holders 4 and it has total shares 427,687. And force of sold out positions holders 2 and it has 197,724s shares.
Comparison with Other Company: The Market Value of IMNP is $24,092 below from AbbVie Inc. market value which is $101M. Current Last Sale of IMNP is $0.1835 below from ABBV current last sale which is $62.22.
Immune pharmaceuticals declared that it has received guidance from america food and Drug management (FDA) on a segment III have a look at for Ceplene in mixture with low dose IL-2 for the preservation of remission in patients with Acute Myeloid Leukemia (AML). Ceplene/IL-2 has formerly been accredited in Europe and Israel following a a hit section III examine with Leukemia loose Survival as the primary endpoint. The projected phase III have a look at layout reviewed through the FDA makes a speciality of usual survival because the primary endpoint, together with key secondary endpoints, counting Leukemia unfastened Survival.
The FDA also offered remarks regardingspecific layout elements of the segment III have a look at, and with this framework, Immune plans to submit the final protocol for the section III look at in early 2017 and, upon approval, proceed with accomplishing a worldwide segment III Pivotal average Survival examine in AML preservation of response with Ceplene/IL2.
“We are very satisfied with the tremendous outcome of our recent interplay with the FDA. Our direction ahead to proceed with a pivotal study following regulatory steerage of Ceplene/IL-2 meets our purpose to cope with the urgent unmet medical need for remission upkeep remedy in AML,” stated Monica Luchi, MD, Immune’s chief clinical Officer.